13F filer · CIK 1352851 ↗
Magnetar Financial LLC
You are looking at Q2 2024. See the latest, Q2 2026 →
Reported value
$4.80B
+7.4% on the quarter before
Positions
497
306 new · 172 sold out
Top 10
23.0%
of the value
Est. gain
−$83.0M
on stocks held all quarter
Est. return
−3.4%
on those stocks since Q1 2024
Positions as of Jun 30, 2024, from Magnetar Financial LLC's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
The 24 largest positions, 45% of the reported value, each sized by its share, colored by what the fund did with it since Q1 2024. Striped tiles are options.
Largest buys
Since Q1 2024, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Sanofi~$111.9MAdded · 0.2% → 2.5%+2,306,286 shares
- Stericycle Inc~$81.6MNew · 0.0% → 1.7%+1,403,679 shares
- Johnson & Johnson~$80.8MNew · 0.0% → 1.7%+552,484 shares
- Solventum Corp~$76.2MAdded · 0.1% → 1.6%+1,440,410 shares
- Championx Corporation~$72.9MNew · 0.0% → 1.5%+2,193,929 shares
- Hashicorp Inc~$71.5MNew · 0.0% → 1.5%+2,121,984 shares
- Cooper Cos Inc~$63.8MNew · 0.0% → 1.3%+731,060 shares
- Marathon Oil Corp~$63.6MNew · 0.0% → 1.3%+2,216,804 shares
- Silk Rd Med Inc~$53.3MNew · 0.0% → 1.1%+1,970,373 shares
- Zimmer Biomet Holdings Inc~$52.6MAdded · 2.4% → 3.0%+484,816 shares
Largest sells
Since Q1 2024, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Medtronic Plc~$94.7MCut · 2.7% → 0.3%−1,202,788 shares
- Pioneer Nat Res Co~$92.6MSold out · 2.1% → 0.0%−352,619 shares
- M D C Hldgs Inc~$87.6MSold out · 2.0% → 0.0%−1,392,641 shares
- Enerplus Corp~$81.9MSold out · 1.8% → 0.0%−4,168,212 shares
- Gsk Plc~$70.8MSold out · 1.6% → 0.0%−1,651,754 shares
- Novartis Ag~$63.9MCut · 4.1% → 2.9%−600,600 shares
- Masonite Intl Corp~$59.8MSold out · 1.3% → 0.0%−454,667 shares
- Astrazeneca Plc~$59.7MSold out · 1.3% → 0.0%−880,833 shares
- Sp Plus Corp~$53.5MSold out · 1.2% → 0.0%−1,025,013 shares
- Conmed Corp~$46.5MSold out · 1.0% → 0.0%−580,508 shares
Holdings
As of Jun 30, 2024. Changes are in shares against Mar 31, 2024, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Zimmer Biomet Holdings IncCOM · shares +59% · price −17.8% | 3.0% | $142.2M | −$19.4M | ||||||||
| Novartis AgSPONSORED ADR · shares −32% · price +10.1% | 2.9% | $139.0M | +$12.7M | ||||||||
| Becton Dickinson & CoCOM · shares +73% · price −5.6% | 2.6% | $123.5M | −$4.2M | ||||||||
| SanofiSPONSORED ADR · shares +1,153% · price −0.2% | 2.5% | $121.6M | −$16,000 | ||||||||
| Elanco Animal Health IncCOM · shares +61% · price −11.4% | 2.5% | $120.3M | −$9.6M | ||||||||
| Globus MedicalCL A · shares +1.7% · price +27.7% | 2.5% | $117.7M | +$25.1M | ||||||||
| Churchill Capital Corp ViiCOM CL A · shares 0% · price +0.7% | 1.9% | $89.5M | +$581,420 | ||||||||
| Juniper Networks IncCOM · shares −0.4% · price −1.6% | 1.8% | $84.7M | −$1.4M | ||||||||
| Westrock CoCOM · shares −8.7% · price +1.6% | 1.7% | $83.4M | +$1.3M | ||||||||
| Stericycle IncCOM · shares New | 1.7% | $81.6M | — | ||||||||
| Abbott LabsCOM · shares +60% · price −8.6% | 1.7% | $81.3M | −$4.8M | ||||||||
| Unitedhealth Group IncCOM · shares +101% · price +2.9% | 1.7% | $81.1M | +$1.2M | ||||||||
| Johnson & JohnsonCOM · shares New | 1.7% | $80.8M | — | ||||||||
| Southwestern Energy CoCOM · shares −3.9% · price −11.2% | 1.7% | $79.9M | −$10.1M | ||||||||
| Solventum CorpCOM SHS · shares +2,881% · price −24.0% | 1.6% | $78.8M | −$833,500 | ||||||||
| Albertsons Cos IncCOMMON STOCK · shares −0.4% · price −7.9% | 1.6% | $77.4M | −$6.6M | ||||||||
| Axonics IncCOM · shares −0.4% · price −2.5% | 1.6% | $76.7M | −$2.0M | ||||||||
| Championx CorporationCOM · shares New | 1.5% | $72.9M | — | ||||||||
| Mcgrath RentcorpCOM · shares −0.4% · price −13.6% | 1.5% | $72.3M | −$11.4M | ||||||||
| Discover Finl SvcsCOM · shares 0% · price −0.2% | 1.5% | $71.5M | −$153,131 | ||||||||
| Hashicorp IncCOM CL A · shares New | 1.5% | $71.5M | — | ||||||||
| Option Care Health IncCOM NEW · shares +125% · price −17.4% | 1.4% | $68.7M | −$6.4M | ||||||||
| Ansys IncCOM · shares −0.4% · price −7.4% | 1.4% | $67.1M | −$5.4M | ||||||||
| Encompass Health CorpCOM · shares +100% · price +3.9% | 1.3% | $63.9M | +$1.2M | ||||||||
| Cooper Cos IncCOM · shares New | 1.3% | $63.8M | — | ||||||||
| Total · 497 positions | 100% | $4.80B | −$83.0M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q1 2024 to Q2 2024: 165 stocks held throughout, down $83.0M (−3.4%).
- Globus Medical+$25.1M+28%
- Adma Biologics Inc+$17.0M+69%
- Novartis Ag+$12.7M+10%
- Olink Hldg Ab+$4.0M+8%
- Mckesson Corp+$3.0M+9%
- Southwestern Energy Co−$10.1M−11%
- Fortrea Hldgs Inc−$10.2M−42%
- Mcgrath Rentcorp−$11.4M−14%
- Enovis Corporation−$11.4M−28%
- Zimmer Biomet Holdings Inc−$19.4M−18%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | $10.96B+11% | SEC ↗ |
| Q1 2026 | May 13, 2026 | $9.84B−4% | SEC ↗ |
| Q4 2025 | Feb 17, 2026 | $10.21B−38% | SEC ↗ |
| Q3 2025 | Nov 13, 2025 | $16.50B−20% | SEC ↗ |
| Q2 2025 | Aug 12, 2025 | $20.65B+171% | SEC ↗ |
| Q1 2025 | May 15, 2025 | $7.61B+75% | SEC ↗ |
| Q4 2024 | Feb 11, 2025 | $4.36B−6% | SEC ↗ |
| Q3 2024 | Nov 13, 2024 | $4.62B−4% | SEC ↗ |
| Q2 2024 | Aug 14, 2024 | $4.80B+7% | SEC ↗ |
| Q1 2024 | May 15, 2024 | $4.47B+13% | SEC ↗ |
| Q4 2023 | Feb 13, 2024 | $3.94B+1% | SEC ↗ |
| Q3 2023 | Nov 14, 2023 | $3.92B−14% | SEC ↗ |
| Q2 2023 | Aug 11, 2023 | $4.56B−11% | SEC ↗ |
| Q1 2023 | May 15, 2023 | $5.13B−13% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $5.91B−18% | SEC ↗ |
| Q3 2022 | Nov 14, 2022 | $7.21B−25% | SEC ↗ |
| Q2 2022 | Aug 15, 2022 | $9.67B+3% | SEC ↗ |
| Q1 2022 | May 16, 2022 | $9.37B−6% | SEC ↗ |
| Q4 2021 | Feb 14, 2022 | $9.96B+1% | SEC ↗ |
| Q3 2021 | Jan 14, 2022 (amended) | $9.82B−7% | SEC ↗ |
| Q2 2021 | Aug 6, 2021 | $10.56B+2% | SEC ↗ |
| Q1 2021 | May 14, 2021 | $10.40B+47% | SEC ↗ |
| Q4 2020 | Feb 12, 2021 | $7.08B+25% | SEC ↗ |
| Q3 2020 | Nov 16, 2020 | $5.66B+67% | SEC ↗ |
| Q2 2020 | Aug 14, 2020 | $3.39B−18% | SEC ↗ |
| Q1 2020 | May 15, 2020 | $4.15B−13% | SEC ↗ |
| Q4 2019 | Feb 13, 2020 | $4.79B+22% | SEC ↗ |
| Q3 2019 | Nov 14, 2019 | $3.93B−21% | SEC ↗ |
| Q2 2019 | Aug 14, 2019 | $5.00B+29% | SEC ↗ |
| Q1 2019 | May 15, 2019 | $3.89B−5% | SEC ↗ |
| Q4 2018 | Feb 14, 2019 | $4.08B−26% | SEC ↗ |
| Q3 2018 | Feb 14, 2019 (amended) | $5.54B−16% | SEC ↗ |
| Q2 2018 | Aug 14, 2018 (amended) | $6.56B+13% | SEC ↗ |
| Q1 2018 | May 15, 2018 (amended) | $5.80B+3% | SEC ↗ |
| Q4 2017 | Feb 14, 2018 (amended) | $5.62B+2% | SEC ↗ |
| Q3 2017 | Nov 14, 2017 (amended) | $5.52B−15% | SEC ↗ |
| Q2 2017 | Aug 14, 2017 (amended) | $6.52B−7% | SEC ↗ |
| Q1 2017 | May 15, 2017 (amended) | $7.02B+1,897% | SEC ↗ |
| Q4 2016 | Aug 14, 2017 (amended) | $351.5M−95% | SEC ↗ |
| Q3 2016 | Nov 14, 2016 (amended) | $7.03B+17% | SEC ↗ |
| Q2 2016 | Aug 15, 2016 (amended) | $6.02B−7% | SEC ↗ |
| Q1 2016 | May 16, 2016 (amended) | $6.49B | SEC ↗ |